# CJC-1295 no DAC + Ipamorelin

> Combination — not ranked · Combos · reviewed 2026-11-08
> Source page: https://peptidemeta.com/p/cjc-1295-no-dac-ipamorelin/

Also known as: Mod GRF 1-29 + Ipamorelin

## Quick answers

**What is CJC-1295 no DAC + Ipamorelin?**

A pulsatile GH secretagogue stack combining short-acting modified GRF with Ipamorelin for physiological GH pulses that more closely mimic natural secretion patterns. CJC-1295 without DAC (modified GRF 1-29, a short-acting GHRH analogue) plus ipamorelin.

**What is in CJC-1295 no DAC + Ipamorelin?**

CJC-1295 no DAC + Ipamorelin typically combines CJC-1295 No DAC and Ipamorelin. Commercial products vary.

**How strong is the evidence for CJC-1295 no DAC + Ipamorelin?**

It is not ranked. A PubMed search found no published studies of this combination; only reviews mention it. Ipamorelin has small human pharmacology studies; published human data on CJC-1295 without DAC (modified GRF 1-29) are scarce.

**Is CJC-1295 no DAC + Ipamorelin FDA-approved?**

No. CJC-1295 no DAC + Ipamorelin is not an approved product; no regulator has reviewed the combination.

**Is CJC-1295 no DAC + Ipamorelin banned in sport?**

Yes. CJC-1295 no DAC + Ipamorelin is prohibited in sport by the World Anti-Doping Agency under S2 (peptide hormones, growth factors, related substances and mimetics).

**How does CJC-1295 no DAC + Ipamorelin work?**

This blend pairs a short-acting GHRH analog (modified GRF 1-29, half-life ~30 min) with the selective GHRP ipamorelin to produce amplified but physiologically pulsatile GH release. The GHRH component activates cAMP/PKA on somatotrophs while ipamorelin activates IP3/PKC via the ghrelin receptor.

**What is known about the safety of CJC-1295 no DAC + Ipamorelin?**

Human safety data are limited: ipamorelin has small human studies, while modified GRF 1-29 has very little published human data. A short-acting profile is expected to cause less sustained IGF-1 elevation than the DAC version.

## Key facts

- **Evidence tier:** not ranked
- **FDA:** not approved
- **WADA:** prohibited (S2)
- **Peptide:** yes
- **Routes studied:** Subcutaneous, Intramuscular
- **Components:** CJC-1295 No DAC, Ipamorelin

## Overview

A pulsatile GH secretagogue stack combining short-acting modified GRF with Ipamorelin for physiological GH pulses that more closely mimic natural secretion patterns.

## Mechanism

This blend pairs a short-acting GHRH analog (modified GRF 1-29, half-life ~30 min) with the selective GHRP ipamorelin to produce amplified but physiologically pulsatile GH release. The GHRH component activates cAMP/PKA on somatotrophs while ipamorelin activates IP3/PKC via the ghrelin receptor. The short duration preserves natural GH pulse patterns and feedback.

## Effects reported in research

_Reported outcomes, not promises; see the evidence tier._

- Pulsatile natural-pattern GH release
- Improved sleep onset and depth
- Reduced body fat with lean mass preservation
- Synergistic GHRH/GHRP amplification

## Safety & unknowns

Human safety data are limited: ipamorelin has small human studies, while modified GRF 1-29 has very little published human data. A short-acting profile is expected to cause less sustained IGF-1 elevation than the DAC version. Reported side effects of GH secretagogues include flushing, headache, and mild water retention. Not FDA-approved.

## Studies

- Raun K, Hansen BS, Johansen NL, et al. (1998). *Ipamorelin, the first selective growth hormone secretagogue*. European Journal of Endocrinology. Preclinical. https://pubmed.ncbi.nlm.nih.gov/9849822/
  Rat and swine study on the ipamorelin component: GH release comparable to GHRP-6 without the ACTH or cortisol rises seen with GHRP-6 and GHRP-2.
- Gobburu JV, Agersø H, Jusko WJ, et al. (1999). *Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers*. Pharmaceutical Research. Clinical trial. https://pubmed.ncbi.nlm.nih.gov/10496658/
  Dose-escalation study of the ipamorelin component in healthy men: half-life about 2 hours, with a single episode of GH release peaking at about 40 minutes.

## Status sources

- [Gobburu et al. 1999 — ipamorelin PK/PD in human volunteers](https://pubmed.ncbi.nlm.nih.gov/10496658/)
- [Review of GH–IGF-1 axis performance-enhancing peptides (Front Endocrinol 2026)](https://pubmed.ncbi.nlm.nih.gov/42395176/)
- [WADA 2026 Prohibited List — S2.2.4 GHRH analogues and GH secretagogues](https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf)

---

Educational reference only — not medical advice. No dosing information is published. Tiers rate the strength of published evidence, not effectiveness or safety.